Detalles de la búsqueda
1.
Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report.
J Oncol Pharm Pract
; 26(7): 1780-1784, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32192389
2.
Ultimate journey of the terminally ill: Ways and pathways of hope.
Can Fam Physician
; 62(8): 648-56, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27521394
3.
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
Breast Cancer Res
; 17(1): 150, 2015 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27391598
4.
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Breast Cancer Res Treat
; 154(3): 509-20, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26567010
5.
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Support Care Cancer
; 20(11): 2661-8, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22382588
6.
Primum non nocere: could the health care system contribute to suffering? In-depth study from the perspective of terminally ill cancer patients.
Can Fam Physician
; 52(12): 1574-5, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17279239
7.
Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available.
Pharmacoeconomics
; 34(9): 889-900, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27002517
8.
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.
Breast Cancer (Auckl)
; 10: 77-84, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27398025
9.
Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.
J Clin Oncol
; 22(5): 864-71, 2004 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14990642
10.
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
J Clin Oncol
; 33(6): 594-601, 2015 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25605862
11.
Recurrence of a non-seminomatous germ cell tumor in the seminal vesicle 20 years after initial diagnosis and treatment.
Can J Urol
; 11(4): 2350-1, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15380057
12.
The nature of suffering and its relief in the terminally ill: a qualitative study.
J Palliat Care
; 20(1): 7-11, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15132070
13.
Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.
Onco Targets Ther
; 7: 1101-10, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24971020
14.
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
J Clin Oncol
; 27(35): 5906-10, 2009 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19858391
15.
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
J Clin Oncol
; 25(23): 3415-20, 2007 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-17606972
16.
Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada.
Support Cancer Ther
; 2(3): 181-7, 2005 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18628170
17.
Hope and noncurative chemotherapies: which affects the other?
J Clin Oncol
; 28(13): 2310-3, 2010 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20194838
Resultados
1 -
17
de 17
1
Próxima >
>>